Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Annexon, Inc. - common stock
(NQ:
ANNX
)
6.475
-0.205 (-3.07%)
Streaming Delayed Price
Updated: 9:34 AM EST, Jan 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Annexon, Inc. - common stock
< Previous
1
2
3
4
Next >
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026
January 12, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Submits Tanruprubart Marketing Authorization Application to the European Medicines Agency for Guillain-Barré Syndrome
January 08, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
November 14, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
November 12, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
November 10, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Participate in Upcoming September Investor Conferences
August 27, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
August 18, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
August 14, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
August 07, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy
July 24, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)
June 18, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Present at the Jefferies Global Healthcare Conference
May 29, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
May 19, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
May 12, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
May 09, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
May 07, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
April 08, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
April 03, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
March 17, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
March 03, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
February 18, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting
February 13, 2025
Data Reinforce Neuroprotective Effect of C1q Blockade with ANX007 Against Inflammation and Neuronal Damage
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
January 13, 2025
From
Annexon Biosciences
Via
GlobeNewswire
Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones
January 10, 2025
Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operations
From
Annexon Biosciences
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
